104 related articles for article (PubMed ID: 26637739)
1. Do somatic mutations in de novo MDS predict for response to treatment?
Schroeder MA; DeZern AE
Hematology Am Soc Hematol Educ Program; 2015; 2015():317-28. PubMed ID: 26637739
[TBL] [Abstract][Full Text] [Related]
2. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
4. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
5. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
Gill H; Leung AY; Kwong YL
Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
7. Clonal cytopenias of undetermined significance: potential predictor of myeloid malignancies?
Vobugari N; Heuston C; Lai C
Clin Adv Hematol Oncol; 2022 Jun; 20(6):375-383. PubMed ID: 35731608
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
9. Genetic abnormalities and pathophysiology of MDS.
Hosono N
Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
11. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.
Bravo GM; Lee E; Merchan B; Kantarjian HM; García-Manero G
Br J Haematol; 2014 Sep; 166(5):646-59. PubMed ID: 24903747
[TBL] [Abstract][Full Text] [Related]
12. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
14. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
Hamilton BK; Visconte V; Jia X; Tabarroki A; Makishima H; Hasrouni E; Abounader D; Kalaycio M; Sekeres MA; Sobecks R; Duong Liu H; Bolwell B; Maciejewski JP; Copelan E; Tiu RV
Am J Hematol; 2016 Jun; 91(4):406-9. PubMed ID: 26799334
[TBL] [Abstract][Full Text] [Related]
15. [Cytogenetic abnormalities of 50 MDS patients by FISH detection and conventional karyotype analysis].
Gao DG; Li BT; Zhou LN; Chen H; Zhang B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1190-4. PubMed ID: 24156432
[TBL] [Abstract][Full Text] [Related]
16. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract][Full Text] [Related]
17. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
19. Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.
Zahid MF; Patnaik MM; Gangat N; Hashmi SK; Rizzieri DA
Eur J Haematol; 2016 Oct; 97(4):313-20. PubMed ID: 27147278
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic place in managing myelodysplastic syndromes: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Eclache V; Lafage-Pochitaloff M; Lefebvre C; Penther D; Raynaud S; Tigaud I
Ann Biol Clin (Paris); 2016 Oct; 74(5):525-534. PubMed ID: 27546835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
